度普利尤单抗与2型炎症慢阻肺患者肺功能改善相关:BOREAS和NOTUS试验的事后分析
本事后分析基于BOREAS和NOTUS两项随机对照试验,评估度普利尤单抗对伴2型炎症的慢阻肺患者肺功能参数的影响。结果显示,与安慰剂相比,度普利尤单抗在12周时改善多个肺功能指标并持续至52周,且基线血嗜酸性粒细胞计数或FeNO较高的患者改善更明显。
要点
- 度普利尤单抗改善伴2型炎症慢阻肺患者的支气管舒张剂前/后FEV1和FVC。
- 肺功能改善在12周出现并持续至52周,不受吸烟状态或肺气肿影响。
- 基线血嗜酸性粒细胞计数或FeNO较高的患者肺功能改善更显著。
核心结论
- 在伴2型炎症的慢阻肺患者中,度普利尤单抗治疗可早期且持续地改善多个肺量计肺功能参数。
研究设计与样本
- BOREAS和NOTUS试验的事后分析,伴2型炎症的慢阻肺患者随机接受度普利尤单抗300 mg(n=938)或安慰剂(n=936)皮下注射每2周一次,共52周。
主要发现
- 度普利尤单抗对比安慰剂在12周时改善支气管舒张剂前FEV1(最小二乘均值差83 mL,95%CI 53-112,P<.0001)并持续至52周。
- 度普利尤单抗对比安慰剂在12周时改善支气管舒张剂后FEV1(71 mL,95%CI 41-101,P<.0001)并持续至52周。
- 度普利尤单抗对比安慰剂在12周时改善支气管舒张剂前FVC(64 mL,95%CI 26-102,P=.0009)并持续至52周。
- 度普利尤单抗对比安慰剂在12周时改善支气管舒张剂后FVC(41 mL,95%CI 3-79,P=.0341)并持续至52周。
- 度普利尤单抗对比安慰剂在12周时改善支气管舒张剂后FEV1/FVC(0.016,95%CI 0.010-0.022,P<.0001)和FEF25%-75%(78 mL/s,95%CI 45-111,P<.0001)并持续至52周。
关键数值与推荐
- 支气管舒张剂前FEV1改善不受吸烟状态或合并肺气肿影响,基线血嗜酸性粒细胞计数或FeNO较高者改善更明显。
- 度普利尤单抗对比安慰剂在12周时支气管舒张剂前FEV1改善>100 mL的患者比例分别为42.2% vs 31.1%,52周为36.9% vs 31.2%。
临床怎么用
- 对于伴2型炎症的慢阻肺患者,度普利尤单抗可作为改善肺功能的治疗选择,尤其基线血嗜酸性粒细胞计数或FeNO较高者可能获益更多。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Type 2 inflammation is present in 20%-40% of patients with chronic obstructive pulmonary disease (COPD). OBJECTIVE: To perform in-depth analyses of the efficacy of dupilumab on lung function parameters in patients with COPD and type 2 inflammation. METHODS: In BOREAS (NCT03930732) and NOTUS (NCT04456673), patients with COPD and type 2 inflammation were randomized to dupilumab 300 mg (n = 938) or placebo (n = 936) subcutaneously every 2 weeks for 52 weeks. MEASUREMENTS AND MAIN RESULTS: Dupilumab versus placebo improved pre-bronchodilator forced expiratory volume in 1 second (FEV1; least squares mean difference: 83 [95% confidence interval (CI): 53-112] mL; P < .0001), post-bronchodilator FEV1 (71 [41-101] mL; P < .0001), pre-bronchodilator forced vital capacity (FVC; 64 [26-102] mL; P = .0009), post-bronchodilator FVC (41 [3-79] mL; P = .0341), post-bronchodilator FEV1/FVC (0.016 [0.010-0.022]; P < .0001), and forced expiratory flow 25%-75% of FVC (78 [45-111] mL/s; P < .0001) at week 12 and sustained to week 52. Improvements in pre-bronchodilator FEV1 were observed regardless of smoking status or the presence of co-existing emphysema; greater improvements were observed in patients with higher baseline eosinophil counts or fractional exhaled nitric oxide. Dupilumab versus placebo achieved >100 mL improvements in pre-bronchodilator FEV1 at week 12 (42.2% vs 31.1%) and week 52 (36.9% vs 31.2%), with a similar proportion for post-bronchodilator FEV1 at weeks 12 and 52. CONCLUSIONS: Dupilumab treatment resulted in early and sustained improvements across multiple spirometric lung function parameters in patients with COPD and type 2 inflammation.
引用
- Han MK, Rabe KF, Sciurba FC, et al. Dupilumab is associated with improved lung functions in patients with COPD and type 2 inflammation: a post hoc analysis of the BOREAS and NOTUS trials. Am J Respir Crit Care Med. 2026. PMID: 42968390. doi:10.1093/ajrccm/aamag572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。